Rectiv

Treatment for Anal Fissure and Fistula

Update: Rectiv (nitroglycerin ointment) Now FDA Approved - June 21, 2011

Cellegesic Granted Priority Review by FDA


FDA Decision on Approvability Now Expected in January 2005

SOUTH SAN FRANCISCO, Calif., October 14, 2004 -- Cellegy Pharmaceuticals, Inc.(NASDAQ:CLGY) announced today that its New Drug Application (NDA) covering the use of Cellegesic (nitroglycerin ointment, 0.4%), for the treatment of pain associated with chronic anal fissure has been granted a "Priority Review" by the U.S. Food and Drug Administration (FDA). Cellegy submitted the Cellegesic NDA on June 30, 2004. The Company has been advised that the FDA will decide on approvability of the NDA in early January 2005.

David Karlin, M.D., Cellegy's Vice President of Clinical Research, said, "The FDA may grant a priority review of an NDA for a product determined to provide a significant therapeutic or public health advance. Priority Reviews are completed in 6 months compared to 10 - 12 months for a standard review. The granting of a Priority Review for Cellegesic recognizes that there is no FDA-approved product on the market for the treatment of chronic anal fissure."

K. Michael Forrest, Cellegy's President and CEO, said, "We are delighted to receive this accelerated review designation for Cellegesic and look forward to interacting with the Agency during the final stages of review."

Three double blind, placebo-controlled, Phase 3 studies comprise the NDA submission. The third study was conducted according to a "Special Protocol Assessment" (SPA) procedure that was agreed upon by Cellegy and the FDA. An SPA is intended to provide assurance that if the pre-specified primary endpoint is achieved and no unexpected, untoward effects are seen, the FDA will approve the product for commercial sale.

About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of gastrointestinal disorders, women's health care conditions, including sexual dysfunction, and certain cancers.

The Company's most advanced product, Cellegesic (nitroglycerin ointment) branded "Rectogesic" outside the United States, is approved in the United Kingdom for the treatment of pain associated with chronic anal fissures. Discussions with potential partners are underway and a launch of Rectogesic is expected in the first half of 2005.

The Company is also pursuing the use of Cellegesic for the treatment of hemorrhoids, as well as dyspareunia, a painful condition that prevents or inhibits sexual intercourse in more than 5 million women in the United States. Currently, there is no effective treatment for dyspareunia.

Posted: October 2004

Related Articles

Rectiv (nitroglycerin) FDA Approval History

View comments

Hide
(web2)